VigiLanz Unveils Automated Safety Event Detection and Reporting

MINNEAPOLIS – (December 6, 2017) – VigiLanz, a digital healthcare intelligence firm, announced today the launch of a state-of-the-art automation solution that helps hospitals optimize safety event reporting and enhance compliance with accreditation requirements. VigiLanz® Dynamic Safety Surveillance transforms clinical data into actionable intelligence, empowering hospitals to achieve greater risk reduction through automated safety event detection, management and analytics.

Patient falls and adverse drug events are the most common safety events, which also include surgical errors, wrong blood products, injuries to employees and visitors, and workplace violence. As many as 440,000 people die annually from hospital errors, injuries, accidents and infections. To help combat these issues, The Joint Commission made safety event reporting a requirement for accreditation, which uses the information to improve quality and safety of its hospitals.

Despite the importance of safety event reporting, hospitals are confronted with several barriers that prevent a comprehensive accounting of adverse occurrences. These include:

  • Limited information on the event
  • The time required to complete incident forms
  • A lack of urgency to report events considered too minor
  • Confusion over reporting responsibilities

VigiLanz Dynamic Safety Surveillance overcomes these obstacles by automating the common approaches to managing, reporting and detecting safety events—including capturing information on serious unsafe conditions and resulting adverse events that previously went unreported.

“Those unreported incidents have the potential to do significant long-term harm, as even minor events can escalate into serious, even deadly, situations,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Over-reliance on humans to identify and report safety events exposes hospitals to repercussions ranging from loss of payment for ‘never events’ and damaged reputations to patient grievances and lawsuits. VigiLanz Dynamic Safety Surveillance mitigates those risks with a powerful set of monitoring and reporting tools that supplement human actions for comprehensive reporting.”

VigiLanz Dynamic Safety Surveillance integrates clinical data from multiple sources with comprehensive detection and investigation tools, automated escalation, and a full library of analytical and reporting tools into a single solution that:

  • Accelerates the event reporting life cycle through customized workflows
  • Converts health data automatically into uniform intelligence for more complete reporting and event detection
  • Provides comprehensive tools for efficient analysis
  • Generates state of the art dashboards for real-time monitoring

“The business of safety reporting starts with an organizational culture that embraces reporting all safety events,” said Dr. Goldsteen. “VigLanz Dynamic Safety Surveillance takes it to the next level with a tool that facilitates communications about all safety events, including those that might otherwise go unreported.”

For a demonstration of its new Safety Surveillance solution, visit VigiLanz in Booth #212 at the IHI National Forum, taking place Dec. 10-13 in Orlando, Fla.

About VigiLanz

Founded in 2001, VigiLanz Corporation ( is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

Palomar Health Leverages VigiLanz to Enhance Rapid Diagnostics for Antibiotic Resistance

Back Story

A healthcare system with breadth and depth

Palomar Health is a comprehensive healthcare system providing a full spectrum of healthcare services to communities in an 850-square-mile region, and a trauma center that covers more than 2,200 square miles of South Riverside and North San Diego County, the largest hospital district in California. In addition to three state-of-the-art hospitals—the 288-bed Palomar Medical Center Escondido, 319-bed Palomar Medical Center Downtown Escondido and 107-bed Palomar Medical Center Poway—the health system offers home health care, surgery, skilled nursing, ambulatory care, behavioral health services, wound care, and community health education programs.

At the forefront of technology, Palomar Health leverages the latest in medical technology without losing sight of the personal side of healthcare. This approach is why Palomar Health is nationally recognized for providing the highest quality of clinical care and access to comprehensive services.


Fighting antibiotic resistance with rapid diagnostics

Antibiotic resistance is growing rapidly, with the Centers for Disease Control and Prevention reporting that at least 2 million people are infected with antibiotic-resistant bacteria each year, 23,000 die as a direct result, and many more die from associated complications. For hospitals, combating these “nightmare bacteria” requires, among other things, rapid diagnosis and appropriate treatment, and closely monitoring resistance patterns within the facility.

“With blood infections, time is life because if you’re not getting the right antibiotic, that bacterium will kill you. It will cause you to go from a regular medicine floor to the ICU, or to progress towards death,” said Mike Kruse, Palomar Health’s manager of Clinical Pharmacy Services. “Keep in mind that bacteria have growing resistance, so we need to know what it is because it’s not going to stay the same over time, nor is it going to be the same between one patient and another.”

But it’s not as simple as accelerating the process. The blood cultures required to identify the correct bacterium, and therefore treatment, typically take 2–3 days. Until then, clinicians can only make their best educated guess.


Determined to reduce the severity of antibiotic resistance, Palomar Health began using the VERIGENE® System to enable rapid diagnostics with the VERIGENE® Gram-Positive and Gram-Negative Blood Culture Tests. Performed directly on positive blood culture bottles, rapid diagnostics rely on simultaneous screening to quickly detect infectious pathogens and drug resistance markers. This speeds detection of certain bacteria that are responsible for some of the most challenging and deadly infectious diseases, such as methicillin-resistant Staphylococcus aureus (MRSA) and gram negative rods such as E. coli. “It’s not quite Star Trek medicine, but it’s exciting enough that you feel as though you’re seeing Star Trek beginning to happen,” said Kruse. “It’s nucleic acid testing and that means at the genetic level, we are looking for pieces of genes that actually tell us what that bacterium is. We are even looking for pieces of genes that tell us the code for antibiotic resistance.”

Like any new technology, though, clinician adoption is imperative to the success of rapid diagnostics. It’s not enough to push the information into the patient’s electronic medical record, or even to push an alert to the clinician at the point of care. It must also be acted upon quickly and appropriately.

“We’d not used rapid diagnostics yet, so you’re not going to have every single provider knowing what to do with the information, or they’re not seeing it fast enough. So, then, what’s the purpose of rapid if it’s not really making rapid decisions?” said Kruse. “That’s where VigiLanz comes in.”


Pair VERIGENE® with VigiLanz

Palomar Health had implemented the VigiLanz clinical surveillance platform approximately two years prior to adding rapid diagnostics. At the time, they sought a solution that would provide “a daily list of tasks for our pharmacists, but also let them tap into clinical decision support so that we could improve the care for our patients and find things that we would not otherwise have found,” said Kruse. “After we’d had it in place for about two years, that’s when we began to use it to innovate.”

Rapid diagnostics is a prime example of the innovation made possible by VigiLanz. There are approximately 30 different iterations of bacteria or resistance patterns identifiable by VERIGENE®. So Palomar Health’s pharmacy team worked closely with the VigiLanz team to build approximately 60 rules to match bacteria with antibiotics, as well as mismatch rules.


“In some cases, it’s just an optimization of therapy, for example an antibiotic might be covered but it’s the most expensive one, or it is one that will cause more side effects,” said Kruse. “But the ones we really worry about are complete non-coverage, where you have bacterium growing and the current antibiotics are not going to cover it at all. That’s what’s exciting when you tie together VERIGENE® and VigiLanz.”